The dramatic improvement in overall survival for childhood acute lymphoblastic
leukemia (ALL) is one of the most notable achievements to date in the fight
against cancer. In the 1960s, only 15% of children survived 5 years from time
of diagnosis, whereas today more than 80% of children are cured.1,2 Many
factors have led to these remarkable results, including identification of
agents active in the treatment of ALL, recognition of sanctuary sites with
routine administration of preventive central nervous system–directed
therapy, increasing emphasis on risk-adapted therapy in which treatment is
tailored to predictive clinical and biological variables, and more recently
intensification of treatment. Participation in clinical trials, a hallmark
of pediatric oncology, identifies the most successful components of therapy
and ensures that all children receive the most advanced, up-to-date treatment.
However, not all children have benefited equally from this progress. Many
reports have documented that children of certain race/ethnic groups have inferior
outcomes. Two reports in this issue of THE JOURNAL focus on this issue and
illustrate some of the challenges of investigating multifaceted clinical relationships.3,4
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 10
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.